Translational research for injectable tissue-engineered bone regeneration using mesenchymal stem cells and platelet-rich plasma: From basic research to clinical case study
Translational research for injectable tissue-engineered bone regeneration using mesenchymal stem cells and platelet-rich plasma: From basic research to clinical case study
复制标题
DOI：
10.3727/000000004783983909
复制
发表时间：
2004-01-01
影响因子：
3.3
通讯作者：
Nagasaka, T
中科院分区：
文献类型：
--
作者：
Yamada, Y;Ueda, M;Nagasaka, T
转化研究涉及将基础科学发现应用于临床密切相关的发现，同时根据临床观察产生科学问题。首先，作为基础研究，我们在狗下颌骨模型中研究了使用间充质干细胞（MSCs）和富血小板血浆（PRP）的组织工程化骨再生。我们还证实了牙种植体中的骨整合与可注射骨之间的相关性。用环钻棒制成的骨缺损植入如下移植材料：PRP、犬MSC（dMSC）和PRP、自体颗粒松质骨和骨髓（PCBM）以及对照（仅缺损）。两个月后，安装了牙科植入物。根据植入后2个月的组织学和组织形态计量学观察，PRP、PCBM、dMSCs/PRP、天然骨和对照组之间在骨-植入物界面处的骨-植入物接触量存在显著差异。dMSC/PRP、天然骨和对照组之间的骨密度也存在显著差异。这些发现表明，与自体PCBM相比，使用dMSC/ PRP的混合物将在种植体治疗中提供良好的结果。然后，我们将这种可注射的组织工程骨应用于三名人类患者的后上颌骨或下颌骨的贴附成形术。植入可注射组织工程骨，同时在缺损区植入2-3枚螺纹钛种植体。本研究的结果表明，用于成形术区域的可注射组织工程骨与同时植入的种植体植入在种植体成功方面提供了稳定和可预测的结果。我们以最小的侵袭性和良好的可塑性再生骨，这可以提供一种临床替代自体骨移植。这可能是从基础研究到临床应用的转化研究的一个很好的案例。
Translational research involves application of basic scientific discoveries into clinically germane findings and, simultaneously, the generation of scientific questions based on clinical observations. At first, as basic research we investigated tissue-engineered bone regeneration using mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP) in a dog mandible model. We also confirmed the correlation between osseointegration in dental implants and the injectable bone. Bone defects made with a trephine bar were implanted with graft materials as follows: PRP, dog MSCs (dMSCs) and PRP, autogenous particulate cancellous bone and marrow (PCBM), and control (defect only). Two months later, dental implants were installed. According to the histological and histomorphometric observations at 2 months after implants, the amount of bone-implant contact at the bone-implant interface was significantly different between the PRP, PCBM, dMSCs/PRP, native bone, and control groups. Significant differences were also found between the dMSCs/PRP, native bone, and control groups in bone density. These findings indicate that the use of a mixture of dMSCs/ PRP will provide good results in implant treatment compared with that achieved by autogenous PCBM. We then applied this injectable tissue-engineered bone to onlay plasty in the posterior maxilla or mandible in three human patients. Injectable tissue-engineered bone was grafted and, simultaneously, 2-3 threaded titanium implants were inserted into the defect area. The results of this investigation indicated that injectable tissue-engineered bone used for the plasty area with simultaneous implant placement provided stable and predictable results in terms of implant success. We regenerated bone with minimal invasiveness and good plasticity, which could provide a clinical alternative to autogenous bone grafts. This might be a good case of translational research from basic research to clinical application.